trending Market Intelligence /marketintelligence/en/news-insights/trending/KIbaRJloULKc2a9yVlOkjg2 content esgSubNav
In This List

ImmunoPrecise appoints replacement after director leaves

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


ImmunoPrecise appoints replacement after director leaves

ImmunoPrecise Antibodies Ltd. said director Thomas D'Orazio stepped down from the board after resigning as CEO and president in November.

The company also appointed Robert Burke as director to replace D'Orazio.

Burke is an emeritus professor at the University of Victoria, where he was a faculty member for over 35 years.

The company said that Burke will assist the board in assessing the scientific efficacy of its strategic acquisitions globally.

The Canadian developer of antibodies has bought at least three companies in last six months including QVQ Holdings BV, U-Protein Express BV and ModiQuest Research BV.